TRCT
AZN icon

Tower Research Capital (TRC)’s AstraZeneca AZN Stock Holding History

Tower Research Capital (TRC)’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9M Buy
80,835
+53,082
+191% +$10.2M 0.41% 32
2025
Q4 		$5.1M Sell
27,753
-83,665
-75% -$14.7M 0.12% 142
2025
Q3 		$17.1M Buy
111,418
+35,959
+48% +$5.44M 0.47% 27
2025
Q2 		$10.5M Buy
75,459
+32,265
+75% +$4.52M 0.28% 54
2025
Q1 		$6.35M Buy
43,194
+22,824
+112% +$3.3M 0.19% 77
2024
Q4 		$2.67M Buy
20,370
+12,189
+149% +$1.71M 0.05% 290
2024
Q3 		$1.27M Sell
8,181
-38,630
-83% -$6.24M 0.03% 427
2024
Q2 		$7.3M Buy
46,811
+37,897
+425% +$5.7M 0.12% 134
2024
Q1 		$1.21M Sell
8,914
-15,407
-63% -$2.04M 0.03% 444
2023
Q4 		$3.28M Buy
24,321
+16,127
+197% +$2.1M 0.04% 366
2023
Q3 		$1.11M Sell
8,194
-13,075
-61% -$1.79M 0.03% 494
2023
Q2 		$3.04M Buy
21,269
+18,640
+709% +$2.74M 0.1% 134
2023
Q1 		$365K Sell
2,629
-261
-9% -$35.1K 0.01% 1019
2022
Q4 		$392K Sell
2,890
-40,145
-93% -$5.03M 0.02% 846
2022
Q3 		$4.72M Buy
43,035
+12,650
+42% +$1.6M 0.08% 202
2022
Q2 		$4.01M Sell
30,385
-18,669
-38% -$2.45M 0.09% 185
2022
Q1 		$6.51M Buy
49,054
+40,095
+448% +$4.81M 0.06% 251
2021
Q4 		$1.04M Sell
8,959
-55
-0.6% -$6.47K 0.02% 678
2021
Q3 		$1.08M Buy
9,014
+6,380
+242% +$743K 0.03% 494
2021
Q2 		$316K Sell
2,634
-8,034
-75% -$881K 0.01% 1561
2021
Q1 		$1.06M Buy
10,668
+529
+5% +$53.2K 0.02% 753
2020
Q4 		$1.01M Buy
10,139
+9,955
+5,410% +$1.05M 0.03% 516
2020
Q3 		$20K Buy
184
+77
+72% +$8.56K ﹤0.01% 3862
2020
Q2 		$11K Sell
107
-4,466
-98% -$461K ﹤0.01% 3956
2020
Q1 		$408K Buy
4,573
+2,894
+172% +$272K 0.02% 499
2019
Q4 		$167K Sell
1,679
-4,017
-71% -$378K 0.01% 662
2019
Q3 		$508K Sell
5,696
-3,343
-37% -$290K 0.03% 568
2019
Q2 		$746K Buy
+9,039
New +$709K 0.05% 347
2019
Q1 		– Sell
-7
Closed -$1K – 3780
2018
Q4 		$1K Sell
7
-3,171
-100% -$248K ﹤0.01% 3545
2018
Q3 		$251K Buy
3,178
+2,966
+1,399% +$224K 0.02% 844
2018
Q2 		$15K Buy
+212
New +$15.3K ﹤0.01% 2578
2018
Q1 		– Sell
-5,249
Closed -$364K – 3243
2017
Q4 		$364K Sell
5,249
-4,867
-48% -$328K 0.05% 377
2017
Q3 		$685K Buy
10,116
+10,050
+15,227% +$635K 0.06% 185
2017
Q2 		$4K Sell
66
-1,875
-97% -$122K ﹤0.01% 2068
2017
Q1 		$121K Buy
1,941
+1,891
+3,782% +$110K 0.01% 412
2016
Q4 		$3K Sell
50
-19,291
-100% -$1.1M ﹤0.01% 3225
2016
Q3 		$1.27M Buy
19,341
+16,850
+676% +$1.1M 0.13% 71
2016
Q2 		$150K Buy
2,491
+2,375
+2,047% +$138K 0.01% 852
2016
Q1 		$7K Buy
+116
New +$6.97K ﹤0.01% 2337
2015
Q4 		– Sell
-1,132
Closed -$72K – 4461
2015
Q3 		$72K Sell
1,132
-2,005
-64% -$132K 0.01% 769
2015
Q2 		$200K Buy
3,137
+2,984
+1,950% +$204K 0.02% 373
2015
Q1 		$10K Sell
153
-495
-76% -$34.4K ﹤0.01% 2773
2014
Q4 		$46K Sell
648
-270
-29% -$19.3K ﹤0.01% 1064
2014
Q3 		$66K Buy
918
+760
+481% +$55.6K 0.01% 1305
2014
Q2 		$12K Sell
158
-2,191
-93% -$158K ﹤0.01% 2192
2014
Q1 		$152K Buy
+2,349
New +$152K 0.02% 502
2013
Q4 		– Sell
-736
Closed -$39K – 4448
2013
Q3 		$39K Sell
736
-1,052
-59% -$52.8K ﹤0.01% 2133
2013
Q2 		$85K Buy
+1,788
New +$91K 0.01% 591

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Tower Research Capital (TRC)'s AZN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its AstraZeneca (AZN) stake by 191% in Q1 2026, buying an estimated $10.2M and bringing the position to 80,835 shares worth $15.9M. The position accounts for 0.41% of the portfolio, ranked #32.

Tower Research Capital (TRC) first reported a position in AZN in Q2 2013 and has held it in 48 quarters since. The position peaked at $17.1M in Q3 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Tower Research Capital (TRC) held 80,835 shares of AstraZeneca worth $15.9M as of Q1 2026.
  • Tower Research Capital (TRC) bought 53,082 AstraZeneca shares in Q1 2026, an estimated $10.2M.
  • AstraZeneca made up 0.41% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #32 holding.
  • Tower Research Capital (TRC) first reported a position in AstraZeneca in Q2 2013 and has held it in 48 quarters since.
  • Tower Research Capital (TRC)'s AstraZeneca position peaked at $17.1M in Q3 2025.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.